Immupharma PLC COLLABORATION WITH IMPERIAL COLLEGE LONDON (7976T)
November 29 2021 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 7976T
Immupharma PLC
29 November 2021
RNS | 29 NOVEMBER 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
COLLABORATION WITH IMPERIAL COLLEGE LONDON
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company,
is very pleased to announce that it has signed a 2-year
collaboration agreement with Imperial College London.
Under the collaboration, Imperial College will provide
significant intellectual input and guidance on a number of
innovative peptide assets being developed at our R&D
subsidiary, ImmuPharma Biotech in Bordeaux.
Dr Tim Franklin, Chief Operating Officer of ImmuPharma, added:
"We are all extremely excited to be working with such a world
leading academic institute. This union will be invaluable in
guiding and progressing our earlier stage product development
portfolio, as well as enhancing our intellectual property
base."
Dr Sébastien Goudreau, Chief Executive Officer of ImmuPharma
Biotech, added: "We are delighted that now with the full support
from the new Board for our innovative research programs, we have
the opportunity of working with collaboration partners which
include world leading academic institutes such as Imperial College
London ."
End
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation no 596/2014
which is part of English law by virtue of the European (withdrawal)
Act 2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman and Chief Executive
Officer + 44 (0) 207 152 4080
Dr Tim Franklin, Chief Operating Officer
Lisa Baderoon, Head of Investor Relations
& Non-Executive Director + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge +44 ( 0) 20 3650 3650
John Howes
Bob Pountney
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases, metabolic diseases, anti-infectives and
cancer. The lead program, Lupuzor(TM), is a first-in class
autophagy immunomodulator which is in Phase 3 for the treatment of
lupus and preclinical analysis suggest therapeutic activity for
many other autoimmune diseases that share the same autophagy
mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
28 November 2019, an exclusive licence and development agreement
and trademark agreement for Lupuzor(TM) to fund a new international
Phase 3 trial for Lupuzor(TM) and commercialise in the US. The
Lupzor(TM) Phase 3 trial is on track to commence in 2022.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
About Imperial College London
Imperial College is a global top ten university with a
world-class reputation in science, engineering, business and
medicine. For more information go to:
https://www.imperial.ac.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCMZMZMVNFGMZM
(END) Dow Jones Newswires
November 29, 2021 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2024 to Jun 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2023 to Jun 2024